Pioneering Science Protected by Patents and Process
- Science & Technology
- OncoVAX® Treatment Schedule
- Manufacturing Process
- Patent Portfolio
- Science Due Diligence
Strong novel patent portfolio
Patent coverage for patient-specific tumor vaccines and human monoclonal antibodies.
- The Vaccinogen portfolio includes twenty (20) approved or issued US patents; and
- Rapid follow-on products based upon experience from pivotal study in
colon carcinoma and Phase I/II data in Stage III colon carcinoma, renal
carcinoma and melanoma.